Towards endoscopic ultrasound and 11C-5-HTP PET screening for pancreatic neuroendocrine tumors in Multiple Endocrine Neoplasia type 1 and Von Hippel Lindau disease - VHLMEN2008

niversitair Medisch Centrum Groningen0 个研究点目标入组 90 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Group A (40 patients)
•- Genetically proven MEN 1 or VHL, or clinically proven MEN1 or VHL also in first grade family members.
•- Signs of a pancreatic tumor biochemically and/or on conventional imaging.
•- The time period between the available conventional imaging data, biochemical markers and the investigational imaging procedures does not exceed 4 months.
•- Over 24 years of age
•- In case of recent surgery at least a 3 months interval between surgery and EUS and 11C-HTP PET scanning.
•- Written informed consent;Group B (50 patients)
•- Genetically proven MEN 1 or VHL, or clinically proven MEN1 or VHL also in first grade family members.
•- No signs of a pancreatic tumor biochemically and/or on conventional imaging
•- The time period between the available conventional imaging data, biochemical markers and the investigational imaging procedures does not exceed 4 months.
•- Over 24 years of age.
•- In case of recent surgery at least a 3 months interval between surgery and EUS and 11C-HTP PET scanning.
•- Written informed consent.

•- Excluded are patients with any signs of neurological or psychiatric disorders that will preclude him/her from expressing her/his own free will.
•- Pregnancy.
•- Patients not eligible for surgical intervention.
•- Patients with alcohol abusus.
•- Patients with chronic pancreatitis.
•- VHL type 2C

发起方